-

Innovaderm Honoured With a CRO Leadership Award Again This Year

Win anchors reputation as a CRO of choice by sponsors

MONTREAL--(BUSINESS WIRE)--Innovaderm is the proud recipient of a 2022 CRO Leadership Award after garnering outstanding support in the Quality and Reliability categories. This is the second consecutive win for the high-achieving dermatology CRO.

“We are very pleased to have been selected once again by our sponsors for this prestigious award and laud our team for their extraordinary work this past year,” says Dr. Robert Bissonnette, Innovaderm’s founder and Chief Executive Officer. “As a leader in therapeutic dermatology, we pride ourselves on the delivery of quality services while driving research forward.”

Presented by Clinical Leader, Life Science Leader, and Industry Standard Research, the CRO Leadership Awards recognize top clinical trial service partners based on feedback from sponsor pharmaceutical and biopharmaceutical companies that outsource clinical trials. This year, 50 contract research organizations were assessed on over 20 performance metrics.

“Innovaderm has a reputation of excellence in clinical research in dermatology,” says Dave Selkirk, Innovaderm’s Chief Operating Officer,“ and this leadership award is a testament to our success in the field.”

To learn about Innovaderm’s services, visit our website.

Innovaderm Research Inc.

Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.

Contacts

Kathy Giangaspero
Communications Specialist
Innovaderm Research Inc.
kgiangaspero@innovaderm.com

Innovaderm Research Inc.


Release Summary
Innovaderm Honoured With a CRO Leadership Award Again This Year

Contacts

Kathy Giangaspero
Communications Specialist
Innovaderm Research Inc.
kgiangaspero@innovaderm.com

Social Media Profiles
More News From Innovaderm Research Inc.

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression

MONTREAL--(BUSINESS WIRE)--Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our g...

Indero Celebrates 25 Years and Looks to the Future of Clinical Research

MONTREAL--(BUSINESS WIRE)--Indero, the niche CRO formerly known as Innovaderm, is celebrating 25 years of advancing clinical research. From its roots as a dermatology site in Montreal, Indero has grown into a global organization with capabilities in more than 30 countries across 4 continents and has earned a reputation for delivering expert, efficient trials in dermatology and, more recently, rheumatology. Indero was founded as Innovaderm in 2000, starting as a clinical site and now a global CR...

Innovaderm Research Rebrands as Indero, a Dual-Focus CRO

MONTREAL--(BUSINESS WIRE)--Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity reinforces the company’s dual focus on rheumatology and dermatology and recognizes the close synergy between these fields. Innovaderm has over 25 years of clinical research experience within dermatology, and recognizes that many inflammatory and autoimmune conditions manifest across both the skin and the musculosk...
Back to Newsroom